Brentuximab Vedotin
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Brentuximab Vedotin: From Hodgkin Lymphoma to Follicular Lymphoma
One-Sentence Summary
Brentuximab vedotin is an anti-CD30 antibody-drug conjugate originally used for Hodgkin lymphoma. The TxGNN model predicts it may be effective for follicular lymphoma, but the supporting evidence is thin and indirect: 6 clinical trials (3 withdrawn or terminated early, 1 small ongoing Phase 2) and 20 publications, most of which concern other lymphomas.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Classical Hodgkin lymphoma (from the knowledge-graph indication list; the Singapore registration record gives no indication text) |
| Predicted New Indication | Follicular lymphoma |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed DrugBank mechanism-of-action data are not available. From the data compiled for this report, brentuximab vedotin is an anti-CD30 antibody-drug conjugate that delivers the cytotoxic payload MMAE to CD30-positive cells. This is why it works in Hodgkin lymphoma, where CD30 is consistently expressed.
Follicular lymphoma is a B-cell lymphoma, so it belongs to the same broad disease family as Hodgkin lymphoma. However, follicular lymphoma is usually CD30-low or CD30-negative, so the mechanistic rationale is weak. Any benefit would depend on CD30 expression in a subset of tumours, or on a "bystander effect" in which released MMAE kills neighbouring CD30-low cells. No validated target-expression link has been established.
The high graph score therefore reflects network proximity to lymphoma indications rather than a demonstrated biological mechanism in follicular lymphoma.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04587687 | Phase 2 | Recruiting | 23 | Brentuximab vedotin + bendamustine in relapsed/refractory follicular lymphoma. This is the only FL-specific trial; no results yet (estimated completion 2028) |
| NCT02594163 | Phase 2 | Terminated | 25 | Randomised trial of rituximab + bendamustine with or without brentuximab vedotin in CD30-positive DLBCL. Design is relevant, but it is underpowered |
| NCT01805037 | Phase 1/2 | Terminated | 20 | Brentuximab vedotin + rituximab as frontline therapy in CD30+ and/or EBV+ lymphomas; not FL-specific |
| NCT02623920 | Phase 2 | Withdrawn | 0 | Brentuximab vedotin + bendamustine + rituximab in CD30+ relapsed/refractory B-cell NHL; never enrolled |
| NCT04138875 | Phase 2 | Withdrawn | 0 | Rituximab + brentuximab vedotin ± bendamustine in post-transplant lymphoproliferative disorder; never enrolled |
| NCT04795869 | Phase 2 | Withdrawn | 0 | Brentuximab vedotin + pembrolizumab in recurrent peripheral T-cell lymphoma; never enrolled |
Literature Evidence
None of the publications reports brentuximab vedotin efficacy in follicular lymphoma. The most relevant are listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38364196 | 2024 | RCT | J Clin Oncol | Final analysis of Ro-CHOP (romidepsin + CHOP vs CHOP) in untreated peripheral T-cell lymphoma; does not test brentuximab vedotin |
| 40758949 | 2025 | Cohort | Blood Adv | Phase 2 brentuximab vedotin + gemcitabine in relapsed/refractory CD30+ PTCL |
| 33320379 | 2021 | Cohort | Eur J Haematol | Brentuximab vedotin + ICE regimen in relapsed/refractory PTCL |
| 38306597 | 2024 | Review | Blood | Treatment approaches in common PTCL subtypes, including brentuximab vedotin + CHP |
| 39644004 | 2024 | Review | Hematology ASH Educ Program | Incorporating brentuximab vedotin and novel agents into PTCL management |
| 35663281 | 2022 | Review | Leuk Res Rep | Immunotherapy in indolent NHL, including follicular lymphoma |
| 28967896 | 2018 | Review | Bone Marrow Transplant | Post-autologous-transplant maintenance in lymphoma, including follicular lymphoma |
| 34797505 | 2022 | Retrospective study | Adv Ther | Real-world brentuximab vedotin + CEP in untreated CD30+ PTCL |
| 32476657 | 2020 | Case report | Gulf J Oncol | Grade I follicular lymphoma transformed to CD30+ ALCL, with complete response to brentuximab vedotin and high-dose methotrexate |
| 41409526 | 2025 | Case report | Skin Appendage Disord | Follicular mucinosis (a skin condition, not follicular lymphoma) responding to brentuximab vedotin |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14477P | ADCETRIS® Powder for Concentrate for Solution for Infusion 50 mg/vial | Injection, powder, for solution | Not stated in the registration record |
The product is a single-ingredient, currently valid registration. The only dosage form is an injectable.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy: antibody-drug conjugate (anti-CD30 antibody with MMAE cytotoxic payload) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions; handle in accordance with local cytotoxic drug handling rules |
Safety Considerations
- Drug Interactions: 100 interactions were recorded; the 20 listed in the data compiled for this report are all rated Moderate. They include:
- Antidiabetic agents: acarbose, albiglutide, alogliptin, metformin, pioglitazone, acetohexamide, chlorpropamide, glimepiride, glipizide, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, dulaglutide, exenatide
- Other drugs: bupropion, chenodeoxycholic acid, clarithromycin, clotrimazole, eliglustat
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The only follicular-lymphoma-specific trial is a small, ongoing Phase 2 study with no results. Three of the six linked trials were withdrawn with no patients, and no publication shows efficacy in follicular lymphoma. CD30 is usually low or absent in this disease, so the mechanistic basis is weak. The high TxGNN score alone does not justify advancing this indication.
For comparison, B-cell neoplasm (the fourth-ranked prediction, mainly CD30-positive DLBCL) has stronger support. It has a completed Phase 2 trial in 176 patients, a randomised Phase 3 trial in relapsed DLBCL that is no longer recruiting (239 patients), and a 2025 J Clin Oncol report of a brentuximab vedotin + lenalidomide + rituximab combination. It could be evaluated as a more promising direction.
To proceed, the following is needed:
- Results from NCT04587687 (brentuximab vedotin + bendamustine in relapsed/refractory follicular lymphoma)
- Data on CD30 expression in follicular lymphoma, to define a biomarker-selected population
- Package insert warnings and contraindications from the Singapore registration, which are currently missing
- Detailed mechanism-of-action data from DrugBank
- Confirmation of the approved indication text for the Singapore registration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.